Outcome of early clinical trials of the combination of hydroxychloroquine with chemotherapy in cancer

por Poklepovic, Andrew, Gewirtz, David A
Publicado em 2014

Considering adjuvant therapy for stage II melanoma

por Poklepovic, Andrew S., Luke, Jason J.
Publicado no Cancer (2019)

Not the comfy chair! Cancer drugs that act against multiple active sites

por Booth, Laurence, Poklepovic, Andrew, Dent, Paul
Publicado no Expert Opin Ther Targets (2019)

Metabolism of Histone Deacetylase Proteins Opsonizes Tumor Cells to Checkpoint Inhibitory Immunotherapies

por Dent, Paul, Booth, Laurence, Poklepovic, Andrew
Publicado no Immunometabolism (2019)

Curcumin interacts with sildenafil to kill GI tumor cells via endoplasmic reticulum stress and reactive oxygen/ nitrogen species

por Roberts, Jane L., Poklepovic, Andrew, Booth, Laurence
Publicado no Oncotarget (2017)

Immunotherapy for Metastatic Melanoma with Right Atrial Involvement in a Patient with Rheumatoid Arthritis

por Benson, Zachary, Gordon, Sarah, Nicolato, Patricia, Poklepovic, Andrew
Publicado no Case Rep Oncol Med (2017)

The CHK1 inhibitor SRA737 synergizes with PARP1 inhibitors to kill carcinoma cells

por Booth, Laurence, Roberts, Jane, Poklepovic, Andrew, Dent, Paul
Publicado no Cancer Biol Ther (2018)

PDE5 inhibitors enhance the lethality of [pemetrexed + sorafenib]

por Booth, Laurence, Roberts, Jane L., Poklepovic, Andrew, Dent, Paul
Publicado no Oncotarget (2017)

[pemetrexed + sildenafil], via autophagy-dependent HDAC downregulation, enhances the immunotherapy response of NSCLC cells

por Booth, Laurence, Roberts, Jane L., Poklepovic, Andrew, Dent, Paul
Publicado no Cancer Biol Ther (2017)

Prior exposure of pancreatic tumors to [sorafenib + vorinostat] enhances the efficacy of an anti-PD-1 antibody

por Booth, Laurence, Roberts, Jane Lisa, Poklepovic, Andrew, Dent, Paul
Publicado no Cancer Biol Ther (2018)

NEDD4 over-expression regulates the afatinib resistant phenotype of NSCLC cells

por Booth, Laurence, Roberts, Jane L., Poklepovic, Andrew, Dent, Paul
Publicado no Oncol Signal (2017)

The Lethality of [Pazopanib + HDAC Inhibitors] Is Enhanced by Neratinib

por Booth, Laurence, Roberts, Jane L., Poklepovic, Andrew, Dent, Paul
Publicado no Front Oncol (2019)

Pazopanib and HDAC inhibitors interact to kill sarcoma cells

por Tavallai, Seyedmehrad, Hamed, Hossein A, Grant, Steven, Poklepovic, Andrew, Dent, Paul
Publicado em 2014

Sorafenib/Regorafenib and Lapatinib interact to kill CNS tumor cells

por Hamed, Hossein A., Tavallai, Seyedmehrad, Grant, Steven, Poklepovic, Andrew, Dent, Paul
Publicado em 2015

Rationally Repurposing Ruxolitinib (Jakafi(®)) as a Solid Tumor Therapeutic

por Tavallai, Mehrad, Booth, Laurence, Roberts, Jane L., Poklepovic, Andrew, Dent, Paul
Publicado no Front Oncol (2016)

PDE5 inhibitors enhance the lethality of pemetrexed through inhibition of multiple chaperone proteins and via the actions of cyclic GMP and nitric oxide

por Booth, Laurence, Roberts, Jane L., Poklepovic, Andrew, Gordon, Sarah, Dent, Paul
Publicado no Oncotarget (2016)

HDAC inhibitors enhance the immunotherapy response of melanoma cells

por Booth, Laurence, Roberts, Jane L., Poklepovic, Andrew, Kirkwood, John, Dent, Paul
Publicado no Oncotarget (2017)

Valproate augments Niraparib killing of tumor cells

por Booth, Laurence, Roberts, Jane L., Rais, Rumeesa, Poklepovic, Andrew, Dent, Paul
Publicado no Cancer Biol Ther (2018)

Unconventional Approaches to Modulating the Immunogenicity of Tumor Cells

por Booth, Laurence, Roberts, Jane L., Kirkwood, John, Poklepovic, Andrew, Dent, Paul
Publicado no Adv Cancer Res (2018)

Fingolimod augments Pemetrexed killing of non-small cell lung cancer and overcomes resistance to ERBB inhibition

por Booth, Laurence, Roberts, Jane L., Spiegel, Sarah, Poklepovic, Andrew, Dent, Paul
Publicado no Cancer Biol Ther (2018)